Actively Recruiting
Randomized Study to Assess Safety and Dose Effects of ICP-332 Compared to Placebo in Adults With Prurigo Nodularis
Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2026-09-14
135
Participants Needed
43
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a drug called ICP-332 in adults with Prurigo Nodularis PN, a skin condition characterized by itchy nodules. This study is a Phase 2 clinical trial designed to compare different doses of ICP-332 against a placebo to better understand its potential benefits and risks for people with PN. Participants are randomly assigned to receive either ICP-332 at doses of 80 mg or 120 mg, or a placebo, with neither the participants nor the researchers knowing which treatment is given to ensure unbiased results. The study involves a 16-week treatment period to assess itch severity, followed by continued assessments up to 40 weeks to monitor skin condition improvements, quality of life, and any side effects. Blood tests will measure how the drug is processed by the body. Throughout the study, participants will be monitored regularly with evaluations of their itch intensity using a numeric scale, skin assessments by doctors, and quality of life questionnaires. Safety will be closely tracked by recording any adverse events. Participants involvement may last up to 40 weeks, including treatment and follow-up periods to gather comprehensive information about ICP-332s impact on Prurigo Nodularis.
CONDITIONS
Brief Title
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Research Team
A
Alexia Lu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here